Post Treatment Lyme Disease Syndrome

Scientific abstract: Though the exact reason for the cause of PTLDS is not known but there is unmet need for developing therapeutic agents. We have identified a drug that kills both stationary phase and drug-tolerant Borellia burgdorferi (Lyme bacteria) at 20 μg/ml. When tested in in vivo, the antibiotic has shown good efficacy against B. burgdorferi infection in C3H/HeN mice model. Furthermore, the antibiotic reduced macrophage infiltration to spleen after 7 days of B. burgdorferi infection and decreases induction of M1 macrophages (NOS2+) with IFN-G+ response, which helps for Lyme disease progression. In addition to it, the antibiotic also reduced proinflammatory mediators responsible for Lyme disease propagation. With a goal to treat Lyme affected patients with the antibiotic, we have developed an oral formulation by encapsulating the antibiotic in alginate beads using ionotropic-external gelation technique and then enteric coated with eudragit S100. Our novel formulation has